Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome

Clinical and Experimental Immunology

Volumn 166, Issue 1, 2011, Pages 55-63

  Bertelli, R ^a   Bodria, M ^a   Nobile, M ^b   Alloisio, S ^b   Barbieri, R ^b   Montobbio, G ^a   Patrone, P ^c   Ghiggeri, G M ^a  

^a G GASLINI INSTITUTE   (Italy)

^b CNR   (Italy)

^c Division of Nephrology   (Italy)

Author keywords

Adenosine; ATP regulatory pathway; Free radicals; Innate immunity; Nephrotic syndrome; Oxidation burst; Proteinuria

Indexed keywords

2 CHLOROADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE TRIPHOSPHATE; APYRASE; CARBENOXOLONE; NUCLEOTIDE; REACTIVE OXYGEN METABOLITE;

ADOLESCENT; ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALE; NEPHROTIC SYNDROME; NEUTROPHIL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADENOSINE TRIPHOSPHATE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANTIGENS, CD; APYRASE; CD4 LYMPHOCYTE COUNT; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FLUORESCEINS; HUMANS; IMMUNITY, INNATE; MALE; NEPHROSIS, LIPOID; NEPHROTIC SYNDROME; NEUTROPHILS; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; REACTIVE OXYGEN SPECIES; RECEPTORS, PURINERGIC P1; RECEPTORS, PURINERGIC P2; RESPIRATORY BURST; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 80052621729     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04441.x     Document Type: Article

References (52)

1. Caridi G, Bertelli R, Carrea A etal. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:2742-6.
2. Caridi G, Bertelli R, Di Duca M etal. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003; 14:1278-86.
3. Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res 2005; 57:54R-61R.
4. Caridi G, Trivelli A, Sanna-Cherchi S, Perfumo F, Ghiggeri GM. Familial forms of nephrotic syndrome. Pediatr Nephrol 2010; 25:241-52.
5. Lagrue G, Xheneumont S, Branellec A, Weil B. Lymphokines and nephrotic syndrome [Letter]. Lancet 1975; 1:271-2.
6. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40:453-60.
7. Ghiggeri GM, Artero M, Carraro M, Perfumo F. Permeability plasma factors in nephrotic syndrome: more than one factor, more than one inhibitor. Nephrol Dial Transplant 2001; 16:882-5.
8. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005; 5:1179-85.
9. Bertelli R, Trivelli A, Magnasco A etal. Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome. Clin Exp Immunol 2010; 161:151-8.
10. Ginevri F, Ghiggeri GM, Candiano G etal. Peroxidative damage of the erythrocyte membrane in children with nephrotic syndrome. Pediatr Nephrol 1989; 3:25-32.
11. Musante L, Candiano G, Petretto A etal. Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol 2007; 18:799-810.
12. Candiano G, Petretto A, Bruschi M etal. The oxido-redox potential of albumin methodological approach and relevance to human diseases. J Proteomics 2009; 73:188-95.
13. Zhou LL, Hou FF, Wang GB etal. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int 2009; 76:1148-60.
14. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008; 57:1446-54.
15. Bertani T, Poggi A, Pozzoni R etal. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest 1982; 46:16-23.
16. Bertani T, Rocchi G, Sacchi G, Mecca G, Remuzzi G. Adriamycin-induced glomerulosclerosis in the rat. Am J Kidney Dis 1986; 7:12-19.
17. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272:26734-41.
18. Bertelli R, Ginevri F, Gusmano R, Ghiggeri GM. Cytotoxic effect of adriamycin and agarose-coupled adriamycin on glomerular epithelial cells: role of free radicals. In Vitro Cell Dev Biol 1991; 27A:799-804.
19. Ginevri F, Gusmano R, Oleggini R etal. Renal purine efflux and xanthine oxidase activity during experimental nephrosis in rats: difference between puromycin aminonucleoside and adriamycin nephrosis. Clin Sci 1990; 78:283-93.
20. Lebrecht D, Setzer B, Rohrbach R, Walker UA. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol Dial Transplant 2004; 19:329-36.
21. Ghiggeri GM, Cercignani G, Ginevri F etal. Puromycin aminonucleoside metabolism by glomeruli and glomerular epithelial cells in vitro. Kidney Int 1991; 40:35-42.
22. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-19.
23. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18:16-28.
24. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM etal. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007; 18:2773-80.
25. Haag F, Adriouch S, Brass A etal. Extracellular NAD and ATP: partners in immune cell modulation. Purinergic Signal 2007; 3:71-81.
26. Pfeiffer ZA, Guerra AN, Hill LM etal. Nucleotide receptor signaling in murine macrophages is linked to reactive oxygen species generation. Free Radic Biol Med 2007; 42:1506-16.
27. Suh BC, Kim JS, Namgung U, Ha H, Kim KT. P2X7 nucleotide receptor mediation of membrane pore formation and superoxide generation in human promyelocytes and neutrophils. J Immunol 2001; 166:6754-63.
28. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996; 272:735-8.
29. Di Virgilio F, Borea PA, Illes P. P2 receptors meet the immune system. Trends Pharmacol Sci 2001; 22:5-7.
30. Di Virgilio F. Purinergic signalling in the immune system. A brief update. Purinergic Signal 2007; 3:1-3.
31. Bertelli R, Ginevri F, Caridi G etal. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314-21.
32. Leach FR, Webster JJ. Commercially available firefly luciferase reagents. Methods Enzymol 1986; 133:51-70.
33. Hyman MC, Petrovic-Djergovic D, Visovatti SH etal. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 2009; 119:1136-49.
34. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC. CD39 and control of cellular immune responses. Purinergic Signal 2007; 3:171-80.
35. Deaglio S, Dwyer KM, Gao W etal. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65.
36. Borsellino G, Kleinewietfeld M, Di Mitri D etal. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-32.
37. Fletcher JM, Lonergan R, Costelloe L etal. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183:7602-10.
38. Dwyer KM, Hanidziar D, Putheti P etal. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010; 10:2410-20.
39. Walrand S, Valeix S, Rodriguez C, Ligot P, Chassagne J, Vasson MP. Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes. Clin Chim Acta 2003; 331:103-10.
40. Kumar V, Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol 2009; 616:7-15.
41. Baraldi PG, Preti D, Tabrizi MA etal. 6)-[(hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5′-N- ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor. Bioorg Med Chem 2007; 15:2514-27.
42. Peng W, Cotrina ML, Han X etal. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 2009; 106:12489-93.
43. Jiang LH, Mackenzie AB, North RA, Surprenant A. Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 2000; 58:82-8.
44. Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, Chessell IP. Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol 2007; 151:103-14.
45. Donnelly-Roberts DL, Jarvis MF. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 2007; 151:571-9.
46. Benfenati V, Caprini M, Nicchia GP etal. Carbenoxolone inhibits volume-regulated anion conductance in cultured rat cortical astroglia. Channels 2009; 3:323-36.
47. Carr AC, Hawkins CL, Thomas SR, Stocker R, Frei B. Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents. Free Radic Biol Med 2001; 30:526-36.
48. Dalle-Donne I, Scaloni A, Giustarini D etal. Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. Mass Spectrom Rev 2005; 24:55-99.
49. Guerra AN, Gavala ML, Chung HS, Bertics PJ. Nucleotide receptor signalling and the generation of reactive oxygen species. Purinergic Signal 2007; 3:39-51.
50. Hewinson J, Moore SF, Glover C, Watts AG, MacKenzie AB. A key role for redox signaling in rapid P2X7 receptor-induced IL-1 beta processing in human monocytes. J Immunol 2008; 180:8410-20.
51. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 2008; 153 (Suppl. 1):S457-64.
52. Musante L, Bruschi M, Candiano G etal. Characterization of oxidation end product of plasma albumin in vivo. Biochem Biophys Res Commun 2006; 349:668-73.